Cryosite Limited (CTE) AI Stock Analysis

• Market Cap: AU$58.57M
• Dividend Yield: N/A
• Average Volume (3M): 1.97K
• Price to Earnings (P/E): 31.1
• Beta (1Y): -0.73
• Revenue Growth: 11.93%
• EPS Growth: 2.39%
• Country: AU
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.02
• Shares Outstanding: 48,809,563
• 10 Day Avg. Volume: 3,337
• 30 Day Avg. Volume: 1,969
• PEG Ratio: 8.08
• Price to Book (P/B): 15.22
• Price to Sales (P/S): 2.58
• P/FCF Ratio: 24.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: AU$1.50 ▲(50.00% Upside)
• Action: Reiterated Date: 02/10/26
• Date: Action: Reiterated 02/10/26

The score is driven mainly by solid financial performance (strong margins and revenue growth) but is held back by weaker cash-flow trends and balance-sheet reliance on debt. Technically, momentum is strong but extremely overbought (very high RSI), increasing near-term risk. Valuation is a drag due to a relatively high P/E and no dividend yield provided.

Positive Factors

High Profitability Margins

Cryosite's high gross (62.98%) and net (13.35%) margins reflect structural pricing power and operational efficiency in temperature‑controlled biorepository services. Sustained margins support reinvestment into facilities and technology, provide a cushion versus volume swings, and improve long‑term resilience of cash generation.

Consistent Revenue Growth

A 9.85% YoY revenue increase evidences durable demand for recurring biostorage and sample management services. Given the subscriptionlike revenue from long‑term storage and ongoing handling fees, steady top‑line growth supports predictable revenue streams and scalable margins over a multi‑quarter horizon.

High Return on Equity

ROE of 78.86% indicates very efficient use of shareholder capital to generate profits in an asset‑light service business. High capital productivity can translate into strong shareholder returns if management maintains disciplined reinvestment and controls leverage, enhancing long‑term value creation.

Negative Factors

Declining Free Cash Flow Growth

A 32.88% decline in free cash flow growth signals weakening cash generation momentum. Reduced FCF constrains the company's ability to internally fund capex, expand facilities, or pay down debt, increasing dependence on external financing and limiting strategic flexibility over the medium term.

Earnings Not Fully Cash‑Backed

OCF falling short of net income indicates that reported earnings are not fully converting to cash, potentially due to accruals or working capital pressures. Persistent conversion gaps raise concerns about earnings quality and may necessitate additional liquidity or financing during growth or stress periods.

Material Leverage Reliance

A D/E near 0.95 and a low equity ratio point to meaningful reliance on debt financing. This reduces financial flexibility, increases interest and refinancing exposure, and can amplify downside risk if cash flows weaken or interest rates rise, constraining longer‑term strategic options.

Cryosite Limited Business Overview & Revenue Model

Company Description

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.

How the Company Makes Money

Cryosite Limited generates revenue primarily through its biobanking services, which involve the collection, processing, and storage of umbilical cord blood and tissue from newborns. This service typically comes with an initial fee for collection and processing, as well as ongoing annual storage fees. Additionally, the company may earn revenue from partnerships with hospitals and healthcare providers that refer clients for its biobanking services. Another key revenue stream includes providing storage solutions for research institutions and biopharmaceutical companies, which require secure storage for biological samples. The company's financial performance may also be influenced by the increasing demand for regenerative medicine and stem cell therapies, driving growth in its core offerings.

Cryosite Limited Financial Statement Overview

Summary

Good profitability and revenue growth (9.85% YoY; net margin 13.35%), but the balance sheet shows relatively higher reliance on debt (D/E 0.95; low equity ratio) and cash flow quality is mixed with declining free cash flow growth (-32.88%) and operating cash flow not fully covering earnings.

Income Statement

Cryosite Limited has demonstrated consistent revenue growth, with a notable 9.85% increase in the latest year. The company maintains strong profitability metrics, with a gross profit margin of 62.98% and a net profit margin of 13.35%. EBIT and EBITDA margins are healthy, indicating efficient operations. However, the slight decline in gross profit margin from the previous year suggests potential cost pressures.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.95, indicating manageable leverage. Return on equity is robust at 78.86%, reflecting effective use of equity to generate profits. However, the equity ratio is relatively low, suggesting a higher reliance on debt financing, which could pose risks if not managed carefully.

Cash Flow

The cash flow statement reveals a decline in free cash flow growth by 32.88%, which is a concern. The operating cash flow to net income ratio is below 1, indicating that not all earnings are being converted into cash. The free cash flow to net income ratio of 71.61% suggests a reasonable conversion of profits into free cash flow, but the declining trend in free cash flow growth warrants attention.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	14.12M	12.61M	11.94M	11.76M	10.02M
Gross Profit	8.89M	7.99M	6.48M	6.27M	5.31M
EBITDA	3.41M	3.04M	2.30M	2.40M	1.65M
Net Income	1.88M	1.84M	1.41M	1.36M	652.57K
Balance Sheet
Total Assets	19.46M	19.71M	22.65M	21.50M	21.99M
Cash, Cash Equivalents and Short-Term Investments	5.06M	4.70M	5.73M	5.34M	3.88M
Total Debt	2.27M	2.44M	2.61M	849.76K	1.07M
Total Liabilities	17.07M	18.26M	19.86M	19.64M	21.17M
Stockholders Equity	2.39M	1.45M	2.78M	1.86M	819.23K
Cash Flow
Free Cash Flow	1.48M	2.44M	1.19M	1.63M	80.07K
Operating Cash Flow	2.06M	2.90M	1.49M	2.49M	476.96K
Investing Cash Flow	-420.00K	727.00K	-1.33M	-863.19K	-396.89K
Financing Cash Flow	-1.29M	-3.50M	-768.00K	-148.99K	-260.78K

Cryosite Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Positive. The current price of 1 is below the 20-day moving average (MA) of 1.16, below the 50-day MA of 1.07, and above the 200-day MA of 0.92, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 92.62 is Negative, neither overbought nor oversold. The STOCH value of 95.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CTE.

Cryosite Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	60 Neutral	AU$58.57M	31.09	98.18%	―	11.93%	2.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAP	49 Neutral	AU$52.98M	-2.55	-40.54%	―	29.60%	33.00%
LDX	48 Neutral	AU$202.27M	-16.15	-111.23%	―	12.96%	40.81%
BDX	45 Neutral	AU$44.17M	-6.12	-97.79%	―	―	23.85%
RHY	43 Neutral	AU$69.21M	-10.09	-501.54%	―	―	56.42%
IIQ	38 Underperform	AU$49.98M	-5.61	-37.78%	―	2.33%	12.50%

Cryosite Limited Corporate Events

Cryosite Expands Capacity with New Facility Acquisition

Cryosite Limited has completed the acquisition of a new freehold facility at Adderley Street, which more than doubles its national storage capacity. This expansion is a key part of Cryosite’s growth strategy, addressing increasing client demand and enhancing business continuity by providing additional storage space for sensitive materials. The new facility will enable Cryosite to pursue new revenue streams and expand its service offerings, including clinical trial storage, cryogenic storage, and secondary packaging. Initial works at the new site will be staged to align with client demand, ensuring operational efficiency.

The most recent analyst rating on (AU:CTE) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cryosite Limited stock, see the AU:CTE Stock Forecast page.